A swollen knee shows inflammation at work, but inflammation that never switches off is different. How inflammation causes cancer comes down to persistent immune signaling and DNA damage, which promote tumors without making cancer inevitable.
The mechanism, the named signaling molecules and the conditions with measured risk are covered below. For the wider picture of food, compounds and lifestyle research, see natural health and cancer prevention research.
What inflammation does and does not explain
Chronic inflammation is an established contributor to cancer, but it is one factor among several, and published estimates differ in what they count. MIT News reports that as many as 1 in 5 cancers are believed to be caused or promoted by inflammation. Cancer Research UK writes that up to 1 in 4 cancers globally are linked to inflammation. A review abstract indexed in the US EPA’s HERO database states that infection and inflammation account for approximately 25% of cancer-causing factors.
Read these as a range, not a contradiction. One figure counts cancers caused or promoted, another counts cancers linked, and the last counts a share of causal factors that includes infection. The practical takeaway is that inflammation matters substantially, yet the evidence describes raised risk rather than certainty.
Several popular assumptions blur this picture. The table separates the most common ones from what the evidence supports.
| Common belief | What the evidence supports | Planning use |
|---|---|---|
| Inflammation is behind most cancers. | Inflammation is believed to cause or promote as many as 1 in 5 cancers. | Treat it as a major contributor alongside other causes, not a single explanation. |
| A chronic inflammatory disease means cancer will follow. | Risk is clearly elevated in some diseases, but progression is not automatic. | Use the risk as a reason for medical follow-up, not for alarm. |
| Lowering inflammation is a general cancer-prevention tactic. | The strongest human evidence concerns COX-2 inhibition in people with inflammatory bowel disease. | Apply the finding to that setting only, and discuss it with a clinician. |
Figures are drawn from MIT News and a Cancer Network review of chronic inflammation and cancer.
How persistent inflammation damages DNA
Chronic inflammation raises cancer risk largely because inflamed tissue is chemically hostile to DNA. Reactive oxygen and nitrogen species produced during inflammation damage not only DNA but also other biomolecules. When exposure is persistent, DNA strand breaks, base modifications and other lesions can build up.
Inflammation-related cancers are characterized by mutagenic lesions such as 8-oxodG and 8-nitroguanine, according to the same review abstract. These lesions matter because a mutagenic lesion can be copied wrongly when a cell divides. MIT researchers tested this with a lesion called 5-chlorocytosine, which is made during inflammation. In their replication test the lesion paired with adenine around 5 percent of the time instead of its usual partner. That is a laboratory replication result, not a cancer risk figure for people, but it shows a concrete route from an inflammatory chemical to a heritable DNA error.
Damage alone does not create a tumor. It supplies the mutations, and the signaling described next helps the affected cells survive and multiply.
IL-6 and NF-kB signaling in tumors
Interleukin-6 (IL-6) is an inflammatory cytokine, a signaling protein released by immune and other cells, and it is one of the best-studied links between inflammation and tumor growth. The Cancer Network review explains that exposure to inflammatory cytokines such as IL-6 and IL-10 activates the signal-transducing STAT proteins, which work together with NF-kB in tumorigenesis.
- IL-6 and STAT3: in a mouse model of inflammatory bowel disease, tumor development was reduced in STAT3-deficient mice and through pharmacologic inhibition of IL-6. This points to IL-6 signaling through STAT3 as a driver of inflammation-linked tumors, though the evidence is from mice.
- NF-kappaB: this transcription factor controls inflammatory gene activity. Its activation in tumors promotes proliferation, blocks apoptosis (programmed cell death) and maintains an inflammatory tumor microenvironment.
- Why markers matter: because cytokines such as IL-6 sit on this pathway, inflammatory markers are a natural focus for research on cancer risk. A marker is a sign of activity on the pathway, not a diagnosis.
The practical reading is that these molecules describe how inflamed tissue can sustain tumor growth. They do not yet amount to a test that tells an individual their cancer risk.
Conditions with a documented cancer link
The clearest risk figures come from diseases in which inflammation persists in one organ. The Cancer Network review and the HERO review abstract describe the following.
- Inflammatory bowel disease: patients have a five- to seven-fold increased risk of colorectal cancer. For ulcerative colitis specifically, nearly 43% develop colorectal cancer after 25 to 35 years, so duration of disease is central to the risk.
- Chronic obstructive pulmonary disease (COPD): smokers with COPD have a 1.3- to 6-fold increased risk of lung cancer compared with smokers without COPD, according to the same review. The comparison is between smokers, so it describes the added effect of COPD rather than smoking.
- Barrett’s esophagus and oral leukoplakia: these are inflammatory conditions in which cancer-related DNA lesions have been documented. The supplied evidence describes the lesions rather than a relative risk.
What happens inside inflamed tissue is not always visible. Cancer Research UK notes that a switch can occur, taking cells towards cancer, and that this can happen without visible signs. For that reason, decisions about monitoring in these conditions are best made with a clinician rather than guided by how the disease feels.
Lowering inflammation and cancer risk
Lowering inflammation can lower cancer risk in specific settings, but the best-quantified evidence comes from medicine, not diet. The Cancer Network review reports that inhibiting COX-2 with NSAIDs reduces the risk of colorectal cancer in humans with inflammatory bowel disease by nearly 80%.
That result suits people who already have IBD and is a topic for their gastroenterologist. It is not a reason for people without a high-risk condition to start taking anti-inflammatory drugs for prevention.
Food-based and plant-compound approaches are an active area of study, and the evidence for each differs. Examples elsewhere on this site include research on polypodium leucotomos skin cancer protection and on nordihydroguaiaretic acid benefits. Judge each on its own evidence rather than assuming that anything labelled anti-inflammatory protects against cancer.
Frequently asked questions
| Question | Answer |
|---|---|
| Who first suggested that inflammation and cancer are linked? | Virchow is credited with suggesting the causal link in the 19th century. |
| How long can chronic inflammation last? | Chronic inflammation can last for weeks, months or even indefinitely, which is why it differs from a short-lived response. |
| Does inflammation damage anything besides DNA sequence? | Yes. Reactive oxygen and nitrogen species also damage proteins and lipids, and chronic inflammation promotes genetic and epigenetic changes. |
